What is iCAD?
Headquartered in Nashua, New Hampshire, iCAD, Inc. (NASDAQ: ICAD) operates at the intersection of artificial intelligence and radiology. The company is best known for its ProFound Breast Health Suite, a comprehensive software solution that leverages deep learning to assist radiologists in mammography analysis, density assessment, and risk evaluation. By integrating these advanced computational tools into standard clinical practice, iCAD aims to reduce diagnostic errors and facilitate earlier intervention for patients. The company's market position is defined by its commitment to evidence-based medicine, ensuring that its AI algorithms are clinically validated to meet the rigorous demands of modern healthcare providers. As the demand for precision medicine grows, iCAD remains a critical vendor for hospitals and imaging centers seeking to enhance diagnostic accuracy through automated, high-performance technology.
How much funding has iCAD raised?
iCAD has raised a total of $37.8M across 3 funding rounds:
Share Placement
$15M
Stock Offering
$10.3M
Stock Offering
$12.5M
Share Placement (2012): $15M with participation from Deerfield
Stock Issuance/Offering (2019): $10.3M, investors not publicly disclosed
Stock Issuance/Offering (2020): $12.5M, investors not publicly disclosed
Key Investors in iCAD
Deerfield
Deerfield Management is an investment firm focused on advancing healthcare through investment, intelligence, and philanthropy. The firm supports companies across the healthcare ecosystem with flexible funding models and drives innovation using AI, data, and market research.
Undisclosed Investors
Undisclosed Investors
What's next for iCAD?
Looking ahead, iCAD is positioned to leverage its recent capital influx to accelerate the development of its next-generation AI diagnostic pipeline. The strategic focus will likely center on expanding the clinical utility of its software beyond breast health, potentially targeting other oncology segments where early detection is paramount. By scaling its R&D efforts and strengthening its commercial footprint, the company aims to solidify its competitive advantage in the global digital health landscape. Investors will be monitoring the firm's ability to integrate its technology into broader health systems and its success in navigating the evolving regulatory environment for AI-based medical devices.
See full iCAD company page
